1. Scrip
  2. >>Business
  3. >>Earnings

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

 
• By Jessica Merrill

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

sunset golden crude pipelines in africa
Regeneron updated investors on its pipeline • Source: Shutterstock

Investors and the public are eagerly awaiting updates on Regeneron Pharmaceuticals, Inc.'s antibody cocktail for the treatment and prevention of SARS-Cov-2, but until data from ongoing late-stage clinical trials become available, developments on that front are largely wait-and-see.

During Regeneron's second quarter earnings call on 5 August, analysts pressed management for more details on the antibody cocktail REGN-COV2, with topics ranging from when data from several ongoing trials will be made public to manufacturing capacity and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.